Total Q4 2025 revenue increased to 57620000, supported by 54300000 in net product revenue including 6200000 from Vafseo, while net loss improved to 12244000 compared to 22804000 in the prior year period.
Total revenue rose to 57620000 from 46497000 year-over-year.
Vafseo generated 6200000 in Q4 net product revenue in its first year of launch.
Auryxia net product revenue increased to 48100000 from 44400000 in Q4 2024.
Net loss narrowed to 12244000 compared to 22804000 in the prior year quarter.
Akebia expects significant Vafseo revenue growth in 2026 driven by expanded access at dialysis organizations, new patient starts, and improved adherence, while anticipating Auryxia revenues to decline due to expanding generic competition.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance